BRAF and melanoma: The aforementioned data suggest that CDKN2A mutations may contribute to melanoma resistance; however, to my knowledge, there are no in vitro data confirming the influence of this gene dysfunction and individual mutations on the sensitivity of melanoma cells to BRAF/MEK inhibitors.